ScripOtsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun
ScripVera Therapeutics reported 36-week results on June 2 from the ORIGIN Phase III clinical trial of its B-cell modulator atacicept in the treatment of immunoglobulin A nephropathy (IgAN) in adults, showi
ScripJust a month into her tenure as CEO at Hansa Biopharma, Renée Aguiar-Lucander has hit the ground running at the Swedish biotech, talking up plans for expansion into the US and unveiling a restructurin
ScripAlthough Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it